載入...
OnabotulinumtoxinA for chronic migraine: a critical appraisal
Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options. OnabotulinumtoxinA (onaBoNTA) is approved for use in a number of disorders. Its benefits and potential use in migraine were observed incidentally while treating patients cosmetically for wri...
Na minha lista:
| 發表在: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492656/ https://ncbi.nlm.nih.gov/pubmed/26170679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S76964 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|